[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immix Biopharma Inc (IMMX)

Immix Biopharma Inc (IMMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 977,223
  • Shares Outstanding, K 71,539
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,440 K
  • EBIT $ -42 M
  • EBITDA $ -41 M
  • 60-Month Beta 0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.11

Options Overview Details

View History
  • Implied Volatility 103.98% (-17.51%)
  • Historical Volatility 88.15%
  • IV Percentile 10%
  • IV Rank 3.92%
  • IV High 1,427.58% on 09/09/25
  • IV Low 50.05% on 08/22/25
  • Expected Move (DTE 25) 2.34 (17.11%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,252
  • Volume Avg (30-Day) 254
  • Put/Call OI Ratio 1.10
  • Today's Open Interest 5,122
  • Open Int (30-Day) 5,206
  • Expected Range 11.32 to 16.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 4
  • High Estimate $-0.16
  • Low Estimate $-0.20
  • Prior Year $-0.24
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.83 +74.58%
on 08/03/26
13.76 -0.65%
on 08/21/26
+5.15 (+60.45%)
since 07/24/26
3-Month
7.65 +78.69%
on 06/08/26
13.76 -0.65%
on 08/21/26
+4.89 (+55.69%)
since 05/22/26
52-Week
1.94 +604.64%
on 09/17/25
13.76 -0.65%
on 08/21/26
+11.48 (+524.20%)
since 08/22/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

NEW YORK , Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX).  Such investors are advised...

IMMX : 13.18 (-3.51%)
Inflation Numbers Due Next Week

Monday U.S. Featured Earnings Simon Property Group, Inc. (NYSE:SPG) (Q2) EPS of $3.18, ...

AMAT : 476.53 (-3.21%)
CSCO : 109.93 (-1.00%)
COHR : 265.35 (-8.35%)
SPG : 219.77 (+0.68%)
CAH : 230.71 (+0.52%)
BN : 41.59 (-0.24%)
LITE : 798.64 (-7.85%)
IMMX : 13.18 (-3.51%)
NTES : 125.08 (-2.41%)
SE : 114.86 (-2.27%)
FERG : 242.20 (-0.02%)
ALC : 73.74 (+0.15%)
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immix Biopharma, Inc. (“Immix” or...

IMMX : 13.18 (-3.51%)
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis,...

IMMX : 13.18 (-3.51%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX).  Such investors are advised...

IMMX : 13.18 (-3.51%)
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”,...

IMMX : 13.18 (-3.51%)
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing...

IMMX : 13.18 (-3.51%)
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  – –   CR rate now 95% (19 of 20 patients)   – –    All CRs reached within...

IMMX : 13.18 (-3.51%)
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis,...

IMMX : 13.18 (-3.51%)
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded...

IMMX : 13.18 (-3.51%)

Business Summary

Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 14.55
2nd Resistance Point 14.15
1st Resistance Point 13.91
Last Price 13.18
1st Support Level 13.27
2nd Support Level 12.87
3rd Support Level 12.63

See More

52-Week High 13.76
Last Price 13.18
Fibonacci 61.8% 9.24
Fibonacci 50% 7.85
Fibonacci 38.2% 6.46
52-Week Low 1.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.